Works about ESTROGEN antagonists


Results: 1069
    1
    2
    3
    4
    5

    ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer

    Published in:
    PLoS Biology, 2012, v. 10, n. 12, p. 1, doi. 10.1371/journal.pbio.1001461
    By:
    • Kalyuga, Maria;
    • Gallego-Ortega, David;
    • Lee, Heather J.;
    • Roden, Daniel L.;
    • Cowley, Mark J.;
    • Caldon, C. Elizabeth;
    • Stone, Andrew;
    • Allerdice, Stephanie L.;
    • Valdes-Mora, Fatima;
    • Launchbury, Rosalind;
    • Statham, Aaron L.;
    • Armstrong, Nicola;
    • Alles, M. Chehani;
    • Young, Adelaide;
    • Egger, Andrea;
    • Au, Wendy;
    • Piggin, Catherine L.;
    • Evans, Cara J.;
    • Ledger, Anita;
    • Brummer, Tilman
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12

    Blinding and bias in a hypnotic clinical trial.

    Published in:
    Human Psychopharmacology: Clinical & Experimental, 2021, v. 36, n. 1, p. 1, doi. 10.1002/hup.2757
    By:
    • McCall, William V.;
    • Benca, Ruth M.;
    • Rumble, Meredith E.;
    • Krystal, Andrew D.
    Publication type:
    Article
    13
    14
    15

    Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen.

    Published in:
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, v. 368, n. 1, p. 41, doi. 10.1007/s00210-003-0766-8
    By:
    • Thomas, Dierk;
    • Gut, Bernd;
    • Karsai, Syrus;
    • Wimmer, Anna-Britt;
    • Wu, Kezhong;
    • Wendt-Nordahl, Gunnar;
    • Zhang, Wei;
    • Kathöfer, Sven;
    • Schoels, Wolfgang;
    • Katus, Hugo A.;
    • Kiehn, Johann;
    • Karle, Christoph A.
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Overview.

    Published in:
    Oncology, 1998, v. 55, p. 3, doi. 10.1159/000055252
    By:
    • Ogata, E.
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Elacestrant (ELA) vs Standard of Care (SOC) in ER+/HER2-- Advanced (adv) or Metastatic Breast Cancer (mBC) With ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial.

    Published in:
    Journal of Oncology Navigation & Survivorship, 2024, v. 15, n. 10, p. 310
    By:
    • Bardia, Aditya;
    • O'Shaughnessy, Joyce;
    • Bidard, Francois-Clement;
    • Aftimos, Phillipe;
    • Cortes, Javier;
    • Lu, Janice;
    • Tonini, Giulia;
    • Thea, Kathy Puyana;
    • Paoli, Alessandro;
    • Kaklamani, Virginia
    Publication type:
    Article
    50